Navidea enrolls 1st patient in Phase III trial of NAV4694

06/27/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals said it has signed up the first patient in a Phase III trial that will test the PET imaging agent NAV4694. The study will evaluate the safety and efficacy of the agent in identifying beta amyloid in end-of-life patients with and without dementia. The study, to eventually include 275 individuals, will compare imaging data during life with autopsy findings.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC